2022
Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity
Nepal M, Taheri H, Li Y, Talebi Z, Uddin M, Jin Y, DiGiacomo D, Gibson A, Lustberg M, Hu S, Sparreboom A. Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity. Cancer Research Communications 2022, 2: 1334-1343. PMID: 36506732, PMCID: PMC9730833, DOI: 10.1158/2767-9764.crc-22-0172.Peer-Reviewed Original ResearchConceptsDRG neuronsPeripheral neurotoxicitySide effectsOxaliplatin-induced peripheral neurotoxicityOxaliplatin-based regimensOxaliplatin-based treatmentPharmacokinetics of oxaliplatinEffect of duloxetineMouse DRG neuronsWild-type miceCytotoxicity of oxaliplatinConcentration-dependent mannerColorectal cancerCancer patientsPlasma levelsOIPNPlasma pharmacokineticsDuloxetinePrevention strategiesTherapeutic candidateOxaliplatinTumor cell linesTranslational feasibilityMiceComplete protectionDuloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis
Chow R, Novosel M, So OW, Bellampalli S, Xiang J, Boldt G, Winquist E, Lock M, Lustberg M, Prsic E. Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis. BMJ Supportive & Palliative Care 2022, 13: 27-34. PMID: 36194493, DOI: 10.1136/spcare-2022-003815.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyTreatment of CIPNDuloxetine usePeripheral neuropathyRisk ratioPrevention of CIPNSystematic reviewUse of duloxetineSummary risk ratiosClinical practice recommendationsHigh-quality trialsDerSimonian-Laird modelComprehensive systematic reviewCochrane CENTRALSafety profileDatabase inceptionHuman trialsDuloxetinePractice recommendationsLimited evidencePreventionTrialsNeuropathyTreatmentReview
2021
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias
Schnell PM, Lustberg MB, Henry NL. Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias. JNCI Cancer Spectrum 2021, 5: pkab018. PMID: 33842832, PMCID: PMC8023424, DOI: 10.1093/jncics/pkab018.Peer-Reviewed Original ResearchConceptsPatient-perceived benefitsAdverse eventsBrief Pain Inventory-Short FormAromatase Inhibitor–Associated ArthralgiaDuloxetine-treated patientsOriginal primary outcomeDouble-blind trialLow-grade toxicityEffect of duloxetineSubgroup of patientsAverage painComparable patientsAppropriate patientsPrimary outcomeMusculoskeletal symptomsBreast cancerPlaceboDuloxetineSide effectsFunctional assessmentPatientsSecondary analysisFavorable effectTreatmentPerceptions of benefits
2014
An updated review of antidepressants with marked serotonergic effects in obsessive–compulsive disorder
Pizarro M, Fontenelle L, Paravidino D, Yücel M, Miguel E, de Menezes G. An updated review of antidepressants with marked serotonergic effects in obsessive–compulsive disorder. Expert Opinion On Pharmacotherapy 2014, 15: 1391-1401. PMID: 24766145, DOI: 10.1517/14656566.2014.914493.Peer-Reviewed Original ResearchConceptsDouble-blind studyObsessive-compulsive disorderPathophysiology of OCDEfficacy of desvenlafaxineEfficacy of antidepressantsShort-term treatmentOlder antidepressantsSerotonergic effectsClinical trialsSerotonergic systemNew agentsAntidepressantsSystematic reviewReliable efficacyEfficacyUpdated reviewClomipramineOCD symptomsDisordersTreatmentCurrent studyReviewSSRIsDuloxetineMirtazapine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply